Grade 3a Follicular Lymphoma — Trials

Grade 3a Follicular Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

38 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: University of Washington
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07731789	Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma	not yet recruiting	Phase 2	30	University of WashingtonOTHER	1	Sep 14, 2026	clinicaltrials
NCT06961500	Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A(PROOF)	not yet recruiting	Phase 2	133	Sun Yat-sen UniversityOTHER	1	May 8, 2025